Search results for " Neonatal"

showing 10 items of 441 documents

Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

2007

The European Task Force for Neuronopathic Gaucher Disease (NGD) met in 2006 to review its 2001 guidelines. Fifty-five patients from five European countries were reviewed; 29 were male and 26 female. The majority of the patients were homozygous for the L444P mutation. All had been on enzyme replacement therapy (ERT). However, there was considerable variation in the dose of ERT, as well as an uneven distribution of risk factors. Thus, the oldest patients were on the lowest doses, and several had had a total splenectomy, while the youngest patients had a high proportion of compound heterozygosity and were on the highest doses, and very few had had a splenectomy. This heterogeneity rendered ana…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsHeterozygoteTime FactorsAdolescentmedicine.medical_treatmentSplenectomyEnzyme TherapyDiseaseCompound heterozygosityCentral nervous system diseaseOlder patientsRisk FactorsGeneticsmedicineTotal splenectomyHumansChildGenetics (clinical)Intelligence TestsChemotherapyGaucher Diseasebusiness.industryHomozygotenutritional and metabolic diseasesEnzyme replacement therapymedicine.diseaseSurgeryTreatment OutcomeChild PreschoolGlucosylceramidaseFemaleNervous System DiseasesbusinessJournal of inherited metabolic disease
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes

2018

AbstractSince the impact of possible prothrombotic factors on blood coagulation resulting from exercise remains elusive, this study investigated the acute effects of middle-distance endurance running on blood coagulation parameters in middle-aged athletes. The study population consisted of 33 male endurance runners who were engaged in a 21.1 km run under competitive conditions. Blood samples were collected before the run, immediately after the run, and 3 hours after run completion. Samples were assessed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor antigen (VWF:Ag), endogenous thrombin potential (area…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyphysical activity030204 cardiovascular system & hematologyFibrinogenRunningblood coagulation03 medical and health sciences0302 clinical medicineVon Willebrand factorEndurance traininghemic and lymphatic diseasesInternal medicineABO blood group systemvon Willebrand FactormedicineHumansExerciseblood coagulation; hemostasis; physical activity; thrombin generation; Adult; Blood Coagulation; Exercise; Factor VIII; Fibrinogen; Humans; Male; Middle Aged; Partial Thromboplastin Time; Physical Endurance; Running; Thrombin; Thrombosis; von Willebrand Factor; AthletesProthrombin timeFactor VIIImedicine.diagnostic_testbiologyChemistryThrombinFibrinogenThrombosisHematologyMiddle Agedprothrombotic factors blood coagulation sportprothrombotic factorsEndocrinologyCoagulationAthletesthrombin generationHemostasishemostasisPhysical Endurancebiology.proteinPartial Thromboplastin TimeCardiology and Cardiovascular Medicinesportcirculatory and respiratory physiology030215 immunologyPartial thromboplastin timemedicine.drug
researchProduct

Parental occupational exposure to organic solvents and anencephaly in Mexico

2009

Objective: To assess the relationship between parental occupational exposure to organic solvents, and the risk of anencephaly in Mexico. Methods: A case-control study was conducted based on the registers of the Epidemiological Surveillance System for Neural Tube Defects in Mexico; 151 cases of anencephaly of ≥20 weeks’ gestation were included. A control, born alive and without any apparent congenital malformations at birth, was selected for each case in the same maternity service in which the case was born. Information on occupational exposures, lifestyle habits, reproductive history, use of medicines, supplementation with multivitamins and folic acid, was obtained by a general questionnair…

AdultMalemedicine.medical_specialtyExposición profesional:Chemicals and Drugs::Chemical Actions and Uses::Specialty Uses of Chemicals::Solvents [Medical Subject Headings]Logistic regressionOccupational safety and healthOccupational medicineRisk FactorsOccupational ExposureEnvironmental healthAnencephaly:Health Care::Environment and Public Health::Public Health::Environmental Pollution::Environmental Exposure::Maternal Exposure [Medical Subject Headings]:Diseases::Congenital Hereditary and Neonatal Diseases and Abnormalities::Congenital Abnormalities::Abnormalities Severe Teratoid::Anencephaly [Medical Subject Headings]medicineHumansMexicoAnencephalyPregnancybusiness.industryPublic Health Environmental and Occupational Health:Health Care::Environment and Public Health::Public Health::Environmental Pollution::Environmental Exposure::Occupational Exposure [Medical Subject Headings]Odds ratioOccupational exposureAnencefaliamedicine.diseaseSolventesSurgeryB vitamins:Geographicals::Geographic Locations::Americas::North America::Mexico [Medical Subject Headings]Maternal ExposureCase-Control StudiesPaternal ExposureSolventsGestationFemalebusinessOccupational and Environmental Medicine
researchProduct

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II

2010

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked, recessive, lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase. It has multisystemic involvement, with manifestations in the brain, upper respiratory tract, heart, abdomen, joints and bones. Bone involvement leads to decreased growth velocity and short stature in nearly all patients. A therapeutic option for patients with MPS II is enzyme replacement therapy (ERT) with idursulfase (Elaprase®). We compared annual growth rates before and during ERT in 18 patients from Mainz, Germany, and Manchester, UK. Group 1 included nine patients who started ERT before 10 years of age; group 2 contained nine patie…

AdultMalemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAdolescentIdursulfaseIduronate SulfatasePlaceboShort staturePlacebosYoung AdultChild DevelopmentClinical Trials Phase II as TopicmedicineGeneticsHumansGenetics(clinical)Enzyme Replacement TherapyMucopolysaccharidosis type IIYoung adultGrowth ChartsChildGenetics (clinical)Mucopolysaccharidosis IIbusiness.industrynutritional and metabolic diseasesHunter syndromeEnzyme replacement therapymedicine.diseaseBody HeightSurgerymedicine.anatomical_structureClinical Trials Phase III as TopicAbdomenOriginal Articlemedicine.symptombusinessmedicine.drugJournal of Inherited Metabolic Disease
researchProduct

De novo 15q21.1q21.2 deletion identified through FBN1 MLPA and refined by 244K array-CGH in a female teenager with incomplete Marfan syndrome

2010

International audience; Interstitial deletions involving the 15q21.1 band are very rare. Only 4 of these cases have been studied using molecular cytogenetic techniques in order to confirm the deletion of the whole FBN1 gene. The presence of clinical features of the Marfan syndrome (MFS) spectrum associated with mental retardation has been described in only 2/4 patients. Here we report on a 16-year-old female referred for suspicion of MFS (positive thumb and wrist sign, scoliosis, joint hyperlaxity, high-arched palate with dental crowding, dysmorphism, mitral insufficiency with dystrophic valve, striae). She had therefore 3 minor criteria according to the Ghent nosology. She also had speech …

AdultMalemusculoskeletal diseasesProbandMarfan syndromecongenital hereditary and neonatal diseases and abnormalitiesAdolescent[SDV]Life Sciences [q-bio]Fibrillin-1BiologyFibrillinsBioinformaticsPolymerase Chain ReactionMarfan SyndromeLoss of heterozygosity03 medical and health sciencesTransforming Growth Factor betaIntellectual DisabilityGeneticsmedicineHumansMultiplex ligation-dependent probe amplificationAlleleChildGeneIn Situ Hybridization FluorescenceGenetics (clinical)Oligonucleotide Array Sequence AnalysisSequence Deletion030304 developmental biologyGeneticsChromosomes Human Pair 15Comparative Genomic Hybridization0303 health sciencesMicrofilament Proteins030305 genetics & heredityGeneral Medicinemedicine.diseasePedigree3. Good healthPhenotypeMutationMicrosatelliteFemaleDNA ProbesHaploinsufficiencyMicrosatellite RepeatsEuropean Journal of Medical Genetics
researchProduct

A Novel Loss-of-Function Mutation (N48K) in the PTEN Gene in a Spanish Patient with Cowden Disease

2003

Cowden disease, also known as multiple hamartoma syndrome, is a rare disease inherited in an autosomal dominant pattern, which confers a high risk of developing breast and thyroid carcinomas. Mutations in PTEN, a tumor suppressor gene located on chromosome 10q23, have been identified in patients with Cowden disease. In this work, the direct sequencing of all coding regions of the PTEN gene led us to the identification of N48K, a new germline PTEN missense mutation, in a patient suffering from Cowden disease. The genetic analysis of 200 chromosomes from healthy individuals revealed that the variant was not common in our population. Moreover, by functional analysis we found that the ability o…

AdultPTENcongenital hereditary and neonatal diseases and abnormalitiesTumor suppressor geneDNA Mutational AnalysisMolecular Sequence DataLoss of Heterozygositygenetic analysisDermatologyProtein Serine-Threonine Kinasesmedicine.disease_causeProto-Oncogene MasBiochemistryGenètica molecularfunctional analysisLoss of heterozygosityStructure-Activity RelationshipProto-Oncogene ProteinsmedicineLeukocytesMissense mutationPTENHumansPoint MutationCowden diseaseAmino Acid SequenceMolecular BiologyTumorsGeneticsMutationbiologySequence Homology Amino AcidPoint mutationTumor Suppressor ProteinsPTEN PhosphohydrolaseMultiple hamartoma syndromeCowden syndromeCell Biologymedicine.diseasePhosphoric Monoester HydrolasesN48KSpainbiology.proteinCancer researchFemaleHamartoma Syndrome MultipleProto-Oncogene Proteins c-akt
researchProduct

[A composite indicator for maternity hospital classification].

2018

OBJECTIVES: to propose a composite indicator for maternity hospital classification. DESIGN: descriptive analysis of maternity hospitals through a composite indicator and analysis of its association with infant readmissions within 30 days from the childbirth. SETTING AND PARTICIPANTS: 56 maternity units in Sicily, accounting for 44.436 newborns in 2014. MAIN OUTCOME MEASURES: infant readmission rates within 30 days from the childbirth. RESULTS: low-level hospitals show higher infant readmission rates (odds ratio: 1.3) which may be seen as a signal of inappropriateness of maternity care. CONCLUSIONS: the proposed indicator allows for a classification of maternity hospitals taking into account…

AdultPatient TransferRegionalizationEpidemiologyCesarean SectionPublic Health Environmental and Occupational HealthInfant NewbornMaternity hospitalHospitals MaternityPatient ReadmissionHealthcare services evaluationLogistic ModelsPregnancyIntensive Care Units NeonatalHumansFemaleSettore SECS-S/05 - Statistica SocialeComposite indicatorSicilyProcedures and Techniques UtilizationQuality Indicators Health CareQuality of Health CareEpidemiologia e prevenzione
researchProduct

Variations in breastfeeding rates for very preterm infants between regions and neonatal units in Europe: results from the MOSAIC cohort

2010

Abstract: Objectives To compare breastfeeding rates at discharge for very preterm infants between European regions and neonatal units, and to identify characteristics associated with breast feeding using multilevel models. Methods Population-based cohort of 3006 very preterm births (2231 weeks of gestation) discharged home from neonatal units in eight European regions in 2003. Results Breastfeeding rates varied from 19% in Burgundy to 70% in Lazio, and were correlated with national rates in the entire newborn population. Women were more likely to breast feed if they were older, primiparous and European; more premature, smaller and multiple babies or those with bronchopulmonary dysplasia wer…

AdultPediatricsmedicine.medical_specialtyBreastfeedingGestational AgeCohort StudiesYoung AdultIntensive careHumansMedicineBronchopulmonary DysplasiaPregnancybusiness.industryObstetricsAge FactorsInfant NewbornObstetrics and GynecologyGestational ageGeneral Medicinemedicine.diseaseEuropeParityBreast FeedingBronchopulmonary dysplasiaPediatrics Perinatology and Child HealthCohortIntensive Care NeonatalFemaleHuman medicinebusinessBreast feedingInfant PrematureCohort studyArchives of Disease in Childhood - Fetal and Neonatal Edition
researchProduct

Tuberous sclerosis complex with oral manifestations: A case report and literature review

2011

Introduction: Tuberous sclerosis complex (TSC) is a neurocutaneous syndrome produced by a number of genetic mutations. The disease is characterized by the development of benign tumors affecting different body systems. The most common oral manifestations of TSC are fibromas, gingival hyperplasia and enamel hypoplasia. Clinical Case: A 35-year-old woman diagnosed with TSC presented with a reactive fibroma of considerable size and rapid growth in the region of the right lower third molar. Discussion: In the present case the association of TSC with dental malpositioning gave rise to a rapidly evolving reactive fibroma of considerable diameter. Few similar cases can be found in the literature. P…

Adultcongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyFibromaMalalties de la bocaTuberous sclerosisTuberous SclerosismedicineHumansneoplasmsGeneral DentistryTumorsGingival Neoplasmsbusiness.industryEsclerosi tuberosaEnamel hypoplasiaHyperplasia:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseFibromesnervous system diseasesstomatognathic diseasesMouth diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASTuberosis sclerosisFemaleSurgeryClinical caseFibromabusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct